Electrophysiological basis for the use of adenosine in the diagnosis and treatment of cardiac arrhythmias

The nucleoside adenosine has increasingly been recognised to be useful in the treatment and diagnosis of cardiac arrhythmias. The most recent articles of Rankin et al. and Till et al. confirm this and provide further evidence of the usefulness and applicability of giving intravenous boluses of adenosine as a therapeutic and diagnostic tool in the short term management of supraventricular arrhythmias.

An understanding of the cellular electrophysiological effects of adenosine was vital in the development of the clinical use of this nucleoside. The potential for developing additional clinical uses for adenosine or related compounds (that is agonists and antagonists) rests on further delineation of the cellular and molecular mechanisms of their action.

Our object is to describe the current knowledge of the cellular electrophysiological actions of adenosine and to provide well established examples in which such knowledge has led to the successful use of this nucleoside in the management of cardiac arrhythmias.

**Basis of action of adenosine**

Adenosine is an endogenous nucleoside whose production is increased in response to stimuli such as hypoxia and ischaemia. In addition to its coronary vasodilatory properties, adenosine has considerable electrophysiological effects on the specialised tissues of the heart—that is the sinoatrial and atrioventricular nodes and working myocardium. Adenosine induced depression of the pacemaker activity of the sinoatrial node and of atrioventricular nodal transmission is responsible for the negative chronotropic (bradycardia) and dromotropic (atrioventricular block) effects caused by the nucleoside. Thus adenosine regulates atrial and ventricular rates independently of each other. In addition to these effects on the specialised tissues, adenosine produces a concentration-dependent shortening of the action potential and hyperpolarisation in the atrial myocardium—effects that are accompanied by a negative inotropic response. On the other hand, in the absence of catecholamine stimulation, adenosine causes no discernible electrophysiological or inotropic effect in ventricular myocardium. So adenosine has no effect unless the adenyl cyclase-cAMP system is first stimulated. However, under conditions of enhanced adenylyl cyclase activity (that is raised concentrations of CAMP), the electrophysiological (including triggered activity) and positive inotropic effects of β adrenergic stimulation are antagonised by adenosine.

The cellular basis for adenosine’s effects in supraventricular tissues is mainly the activation of a specific potassium-outward current (I_{KAD})—that is the so-called acetylcholine regulated potassium channels. Other mechanisms of action of adenosine include inhibition of the catecholamine stimulated calcium inward current (I_{Ca}) and in sinoatrial node cells attenuation of the pacemaker current (I_{p}) stimulated by isoprenaline. In contrast, the figure shows that the acetylcholine regulated potassium channels are not present in ventricular myocytes; the electrophysiological actions of adenosine in these cells are mainly caused by the attenuation of catecholamine stimulated I_{Ca} and catecholamine induced transient inward currents (I_{T}), which is responsible for the delayed afterpotentials that often lead to trigger activity. Pacemaker activity arising from Purkinje fibres, stimulated by catecholamines, can also be depressed by adenosine.

**Clinical actions of adenosine**

These electrophysiological properties of adenosine, for the most part, form the basis for its clinical antiarrhythmic actions. Adenosine has proved to be effective (>90%) in terminating supraventricular tachycardia in which the atrioventricular node forms one of the limbs of the reentrant circuit, such as atrioventricular reciprocating tachycardia and atrioventricular nodal reentry. By transiently interrupting impulse propagation through the atrioventricular node, adenosine effectively terminates these types of supraventricular arrhythmias. Some accessory pathways with decremental conduction properties have also been shown to be sensitive to adenosine, which could explain the adenosine induced termination of long RP' tachycardia in the retrograde limb of the reentrant circuit reported by Till et al.

Transient atrioventricular block caused by adenosine has also been shown to be useful in unmasking atrial rhythms (for example, atrial tachycardia and flutter) that are otherwise concealed by the ventricular depolarisations. In addition, in atrial tissue, hyperpolarisation (caused by an increase in I_{KAD}) caused by adenosine may stabilise membrane potential—that is, decrease excitability. Whether this potential effect is responsible for the termination of focal atrial tachycardia as those reported by Perelman and Krikler remains to be established.
Also of importance and consistent with its ability to abolish catecholamine-facilitated triggered activity in isolated ventricular myocytes, adenosine has been shown to terminate episodes of ventricular tachycardia in a distinct subset of patients—those with exertion-related sustained ventricular tachycardia and normal hearts.2 This effect of adenosine seems to be specific for this mechanism of ventricular tachycardia because so far it has been ineffective in ventricular tachycardias thought to be caused by reentry or enhanced automaticity.3 This important action of adenosine combined with its rather specific effect on the atrioventricular node provides very useful diagnostic information for wide-complex tachycardia as clearly shown in recent studies.4

A major clinical advantage of adenosine is that its side effects are transitory (seconds) and relatively benign, because of its rapid cellular metabolism. Side effects predominantly include flushing, dyspnea, and chest pain. Atrioventricular block may also occur, but is seldom symptomatic. Rankin et al5 reported considerably more mild (63%) and severe (36%) side effects with injections of adenosine boluses than did earlier studies, including a recent trial in the United States of 358 patients.6 7 In the earlier studies, the overall incidence of mild side effects was approximately 20-29% and severe side effects < 0.5%; all were transient and did not require treatment.1 8 A possible explanation for the discrepancy in incidence of side effects is that in the study of Rankin et al5 the doses of adenosine used were as high as 20 to 25 mg, whereas in the trial in the United-States8 the maximum dose was 12 mg. Nevertheless, the fact that adenosine has been shown to terminate paroxysmal supraventricular tachycardia without complications in haemodynamically compromised children is consistent with adenosine's high degree of safety.9 10

Conclusion
There are still many potential electrophysiological mechanisms that can account for the antiarrhythmic properties of adenosine; however, further investigation is needed to ascertain not only which of the mechanisms are clinically relevant, but also the pathophysiological role of adenosine in the genesis of disturbances of cardiac rhythm.11 12 Therefore, the development of selective adenosine related compounds (that are agonists and antagonists) and other modulators may become a fruitful area of investigation that could lead to other approaches to the treatment and diagnosis of cardiac arrhythmias.

LUIZ BELARDINELLI

Departments of Medicine and Pharmacology, University of Florida, Gainesville, Florida, USA

BRUCE B LERMAN

Division of Cardiology, Department of Medicine, The New York Hospital, Cornell Medical Centre, New York, USA

The original work described in this review was supported by grants from the National Institutes of Health and the American Heart Association/Florida Affiliate and Suncoast Chapter. B B L is the recipient of an Established Investigatorship Award from the American Heart Association. His present address is The New York Hospital—Cornell Medical Center, Division of Cardiology, 525 East 68th Street, Starr 4, New York, NY 10021, USA.

Correspondence to Dr Luiz Belardinelli, Department of Medicine, Box J-277 JHIMHC, University of Florida, Gainesville, Florida 32610, USA.